课题基金 / 基金详情

Understanding the treatment benefits of novel antiviral agents for hepatitis C: quality of life, health utility, cost, and return to work

Understanding the treatment benefits of novel antiviral agents for hepatitis C: quality of life, health utility, cost, and return to work
了解新型抗病毒药物治疗丙型肝炎的益处：生活质量、健康效用、成本和重返工作岗位
批准号：
346614
负责人：
Wong William Wai Lun
金额：
$34.25万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-03-01 至 2019-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=346614&lang=en
关键词：
Cost-Effectiveness Direct-Acting Antiviral Therapies Hepatitis C Out-Of-Pocket Costs Preferences Quality Of Life Time Costs Utility

项目摘要

项目成果

Wong William Wai Lun的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hepatitis C virus (HCV) has been identified as having the highest health burden of any infectious disease pathogen. Direct-acting antiviral agents (DAAs) are new drugs that offer the promise of cure and substantially improved tolerability. Because of the
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Towards establishing accurate estimates of national chronic hepatitis B prevalence and undiagnosed proportion in Canada
  • 批准号：
    488763
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2023
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
Developing policy models for sexually transmitted and blood-borne infection: integrating best evidence of effectiveness, safety, cost, and patient preferences
  • 批准号：
    499040
  • 项目类别：
    Salary Programs
  • 资助金额：
    $83.78万
  • 财政年份：
    2023
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
Evaluating the impact of direct-acting antiviral treatment access policy on chronic hepatitis C prevalence and the undiagnosed proportion
  • 批准号：
    475136
  • 项目类别：
    Operating Grants
  • 资助金额：
    $10.93万
  • 财政年份：
    2022
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
  • 批准号：
    456739
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2021
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
海外基金